Wells Fargo & Company Dermata Therapeutics, Inc. Transaction History

Wells Fargo & Company

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.18 - $184.8 $3 - $3,696	20 Added 0.08%	24,438 $10,000
Q3 2022 Nov 14, 2022	BUY	$0.1 - $196.8 $1,339 - $2.64 Million	13,395 Added 121.52%	24,418 $13,000
Q2 2022 Aug 12, 2022	BUY	$115.2 - $319.2 $806 - $2,234	7 Added 0.06%	11,023 $7,000
Q1 2022 May 16, 2022	BUY	$223.2 - $571.2 $2.46 Million - $6.28 Million	11,000 Added 68750.0%	11,016 $14,000
Q3 2021 Nov 15, 2021	BUY	$1000.8 - $1392.0 $16,012 - $22,272	16 New	16 $0

Ticker DRMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,102,200
Market Cap $13.5M
Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.